What is Glibenclamide used for?

Glibenclamide is evaluated for the following indications with varying evidence strength: Neonatal diabetes (monogenic forms) (evidence tier A), Type 2 diabetes mellitus (evidence tier B), Gestational diabetes mellitus (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Glibenclamide?

Common side effects of Glibenclamide (≥ 1 in 100): Hypoglycemia, Weight gain of 2–4 kg in the first months of therapy, Nausea, dyspepsia, Rash, pruritus. See the Safety section for uncommon and serious reactions.

Who should not take Glibenclamide?

Glibenclamide is contraindicated in: Type 1 diabetes; Diabetic ketoacidosis, precoma, coma; Severe renal impairment (eGFR < 30 mL/min/1.73 m²); Severe hepatic impairment; Pregnancy, lactation. Full list in the Safety section.

In patients with neonatal diabetes due to activating mutations in KCNJ11 or ABCC8, glibenclamide replaces insulin and restores physiologic glycemic regulation. The mechanism: sulfonylurea closes the mutant ATP-sensitive potassium channel of the β-cell and restores glucose-responsive insulin secretion. Switching from insulin to glibenclamide in these patients is supported by international expert groups (ISPAD 2022, Diabetologia 2006 Pearson) at doses higher than standard adult dosing, up to 1–2 mg/kg daily.

Type 2 diabetes mellitus

Second line

Glibenclamide is a long-experienced sulfonylurea oral hypoglycemic agent. Reduces by 1.0–1.5% as monotherapy. 2024 and ADA/ 2022 do not recommend sulfonylureas as first choice in T2D due to increased hypoglycemia risk and lack of cardiovascular benefit. Metformin, SGLT2 inhibitors and GLP-1 RAs are preferred. Glibenclamide remains on the market as a low-cost alternative when modern drugs are not accessible.

Not used at eGFR < 60 mL/min/1.73 m² due to accumulation of active metabolites and risk of prolonged hypoglycemia. Patients at hypoglycemia risk (irregular meals, advanced age, exercise without dose adjustment) should not receive glibenclamide.

Sources

Gestational diabetes mellitus

Not recommended

Glibenclamide is not first-line for gestational diabetes. 2024 and Russian clinical guidelines specify insulin as the agent of choice. Metformin is a possible alternative in selected patients after discussion with the endocrinologist and obstetrician. Glibenclamide crosses the placenta in clinically significant amounts and is associated with higher rates of neonatal hypoglycemia and fetal macrosomia versus insulin (Cochrane 2017).

If a patient with prepregnancy type 2 diabetes was on glibenclamide, switch to insulin at the planning stage or when pregnancy is confirmed.

Sources

ADA: Standards of Care in Diabetes 2024 (2024)

Type 2 diabetes in elderly patients

Not recommended

Glibenclamide is not used in patients over 65. The 2023 Beers Criteria classify the drug as «avoid in older adults» due to high risk of prolonged hypoglycemia. Active metabolites accumulate with age-related eGFR decline, thyroid disorders and dehydration, sharply increasing severe hypoglycemia risk – a leading cause of falls and hospitalizations in older diabetic patients.

Sources

Timing and administration

Taken 15–30 minutes before breakfast. Doses above 5 mg daily are split between breakfast and dinner. Skipping a meal after dosing causes hypoglycemia.

Monitoring

is checked every 3 months until target is met, then every 6 months. Self-monitoring of blood glucose is mandatory, especially with changes in exercise, diet or intercurrent illness. eGFR is assessed at least annually. With declining renal function, switch to an agent less dependent on renal excretion (gliclazide MR) or to a different class.

Special situations

The patient is taught to recognize hypoglycemia symptoms (sweating, tremor, hunger, palpitations, confusion) and to treat them with fast carbohydrates. In severe hypoglycemia – injectable glucagon and emergency medical care. On glibenclamide, hypoglycemia may be prolonged and recurrent, requiring multi-hour observation and glucose infusion.

Drug interactions

Enhance effect and hypoglycemia risk: beta blockers (mask symptoms), ACE inhibitors, fibrates, fluconazole, co-trimoxazole, warfarin. Reduce effect: glucocorticoids, thiazide diuretics, thyroid hormones, sympathomimetics. Alcohol increases hypoglycemia risk and may produce a disulfiram-like reaction.

Common myths

Myth: «glibenclamide is the most effective glucose-lowering drug because it has been used the longest». Fact: efficacy is comparable to other sulfonylureas and metformin, but risk and tolerability are worse.

Myth: «if you skip a meal, just skip the pill». Fact: glibenclamide is long-acting; skipping a meal after a morning dose carries hypoglycemia risk at 12–14 h.

Myth: «if it does not work, just increase the dose». Fact: with inadequate response, add a different class (metformin, SGLT2 inhibitors). Escalating sulfonylurea dose gives little benefit but increases hypoglycemia risk.

Moderate

propranolol

Non-selective beta blocker

Mechanism

Бета-блокаторы маскируют адренергические симптомы гипогликемии (тахикардия, тремор), оставляя только потливость. Риск тяжелой гипогликемии без предупреждения.

Management

Информировать пациента о подмене симптомов. По возможности – кардиоселективные бета-блокаторы (бисопролол, метопролол) в минимальных дозах.

Sources

ADA: Standards of Care in Diabetes 2024 (2024)

Pair details →

Contraindications

Type 1 diabetes
Diabetic ketoacidosis, precoma, coma
Severe renal impairment (eGFR < 30 mL/min/1.73 m²)
Severe hepatic impairment
Pregnancy, lactation
Glucose-6-phosphate dehydrogenase deficiency
Hypersensitivity to sulfonylureas and sulfonamides

Serious adverse effects

Severe prolonged hypoglycemia with coma and neurological sequelae
Hemolytic anemia in G6PD deficiency
Hyponatremia, SIADH
Severe cutaneous reactions (Stevens-Johnson syndrome)

Common adverse effects

Hypoglycemia
Weight gain of 2–4 kg in the first months of therapy
Nausea, dyspepsia
Rash, pruritus

Uncommon adverse effects

Leukopenia, thrombocytopenia
Cholestatic jaundice
Photosensitivity

PregnancyFDA C

FDA category C. Glibenclamide is not used during pregnancy. Oral hypoglycemic agents are replaced with insulin in pregnant patients per ADA and Russian standards. In gestational diabetes, insulin is preferred; metformin is a possible alternative, but glibenclamide is not.

Breastfeeding

Passes into breast milk in small amounts, but a risk of neonatal hypoglycemia exists. Not used during breastfeeding; replaced with insulin or metformin.

Glibenclamide

Mechanism of action

Indications

Neonatal diabetes (monogenic forms)

Type 2 diabetes mellitus

Gestational diabetes mellitus

Type 2 diabetes in elderly patients

Practical notes

Timing and administration

Monitoring

Special situations

Drug interactions

Common myths

Drug–drug interactions

propranolol

Safety

Contraindications

Serious adverse effects

Common adverse effects

Uncommon adverse effects

PregnancyFDA C

Breastfeeding

Frequently asked